Back to top
more

Artivion (AORT)

(Delayed Data from NYSE)

$26.60 USD

26.60
297,146

+0.60 (2.31%)

Updated Jul 11, 2024 04:00 PM ET

After-Market: $26.63 +0.03 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (153 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?

by Zacks Equity Research

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Artivion (AORT) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 200% and 5.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Is Artivion (AORT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.

Artivion, Inc. (AORT) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Are Medical Stocks Lagging Artivion (AORT) This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.

Derek Lewis headshot

3 Buy-Rated Small Caps Flexing Big Growth

by Derek Lewis

Small-cap stocks can be solid considerations for those who can handle a higher level of volatility. Analysts have recently become bullish on these three.

Nalak Das headshot

Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.

AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is Artivion (AORT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Wall Street Analysts Think Artivion (AORT) Could Surge 30.7%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Artivion (AORT) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 184.62% and 4.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Align Technology (ALGN) and Artivion (AORT) have performed compared to their sector so far this year.

Is Intuitive Surgical (ISRG) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Intuitive Surgical, Inc. (ISRG) and Artivion (AORT) have performed compared to their sector so far this year.

Has AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AN2 Therapeutics, Inc. (ANTX) and Artivion (AORT) have performed compared to their sector so far this year.

Wall Street Analysts Believe Artivion (AORT) Could Rally 44.41%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 44.4% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Artivion (AORT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Augmedix, Inc. (AUGX) have performed compared to their sector so far this year.

Molina Healthcare (MOH) Wins Medicaid Deal From New Mexico HSD

by Zacks Equity Research

Molina Healthcare (MOH) receives a contract from the New Mexico HSD, subsequent to which it can effectively serve the statewide Medicaid members.

Shaun Pruitt headshot

Time to Buy These Medical Stocks as Earnings Approach

by Shaun Pruitt

Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.

Does Artivion (AORT) Have the Potential to Rally 52.78% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 52.8% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Artivion (AORT) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 500% and 5.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Artivion (AORT) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 166.67% and 2.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Sight Sciences, Inc. (SGHT): Can Its 5.6% Jump Turn into More Strength?

by Zacks Equity Research

Sight Sciences, Inc. (SGHT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.